Acusense Launches LLM & XAI for Smarter Health Management
Acusense recently participated in the "Home-Based Healthcare Technology Empowerment" event, co-hosted by the Institute for Information Industry (III) and National Cheng Kung University. Held at the Grand Hi-Lai Hotel, the event brought together medical experts, technology developers, and policymakers from across the country to explore the latest developments and future trends in telemedicine and home healthcare technologies.
Acusense’s keynote presentation drew widespread attention during the event. The company showcased its cutting-edge generative AI technology platform and the application of smart medical devices, while also sharing successful use cases in decentralized clinical trials and healthcare interoperability. A particular emphasis was placed on the application of these technologies in telemedicine, especially their role in improving patient quality of life and advancing health equity.
Acusense’s generative AI technology plays a pivotal role in chronic disease management. Integrating Large Multimodal Models (LMM) and Explainable AI (XAI), the technology is designed to significantly enhance the quality of long-term health management. It focuses on improving the effectiveness of chronic care by helping healthcare providers and patients manage long-term health conditions more efficiently.
The AI system can generate personalized health recommendation reports based on a patient’s data and medical history, offering optimal treatment plans. It also sends automated reminders and educational content tailored to the patient’s condition, ensuring continuous guidance. Additionally, the system features an automated scoring function that accurately evaluates patient health indicators. It supports the generation of long-term health reports with detailed data analysis and can automatically produce hypotension risk assessments during dialysis based on blood pressure data, enhancing patient safety.
By leveraging LMM and XAI technologies, Acusense not only improves the accuracy and effectiveness of chronic disease care but also makes the medical decision-making process more transparent and interpretable. These innovations further reinforce Acusense’s leadership in the medical technology field and foster deeper collaboration with industry partners.
Moreover, Acusense’s generative AI technology has been successfully accepted into the NVIDIA Inception Program, providing the company with strong technical support for further AI advancements. Its technological and research achievements have also received widespread recognition from both academia and industry. Notably, Acusense has published two award-winning papers at IEEE conferences and ranked among the top 20 teams—out of 263 nationwide—in the National Science and Technology Council’s “GenAI for All Industries” Startup Competition. These accomplishments mark Acusense as a rising star in the field.
Looking ahead, Acusense remains committed to the development and application of generative AI technologies, with the goal of delivering superior health management solutions to more healthcare institutions and patients.
